**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An 80-year-old man developed COVID-19 infection during treatment with immune-globulin and azathioprine for myasthenia gravis. Additionally, he developed myasthenic crisis during off-label treatment with hydroxychloroquine and azithromycin for COVID-19 \[*doses and time to reactions onsets not stated; not all routes and outcomes stated*\].

The man had a history of diabetes, hypertension and myasthenia gravis. He had been receiving IV immune-globulin monthly and azathioprine for myasthenia gravis. He presented to the hospital with oxygen saturation of 88%, respiratory distress, fever and increased work of breathing. A chest radiography revealed bilateral lower lobe opacities and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR testing was positive. He was intubated on the day of arrival for hypoxic respiratory failure and managed for COVID-19. To treat COVID-19, he received azithromycin for 4 days and hydroxychloroquine for 7 days. Azathioprine was held. Following 6 days of mechanical ventilation, he was successfully extubated to a non-rebreather mask and he had oxygen saturation between 90% and 100%. Four days after extubation, his mental status and ability to participate in self-care declined, and an aspiration event required re-intubation. It was unclear whether his acute decompensation was representative of a biphasic evolution of COVID-19 infection or complications of myasthenia gravis. Serial physical examinations demonstrated a progressive proximal limb weakness with preserved distal limb reflexes. Vital capacity measured at that time was approximately 15 mL/kg, and he was diagnosed with myasthenic crisis.

The man\'s treatment with hydroxychloroquine was stopped. He was commenced on pyridostigmine. Additionally, he received immune-globulin daily for 5 days. Despite some return of strength, minimal FiO~2~ and positive end expiratory pressure requirements, he failed multiple spontaneous breathing trials and ultimately required open surgical tracheostomy on day 20 of admission. Repeat COVID-19 testing 3 weeks following the admission remained positive.
